Taste, pain, or response to stress—nearly all essential functions in the human body are regulated by molecular switches ...

Vanda Pharmaceuticals Inc. (Vanda) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysantitm (milsaperidone) has been filed, and ...

DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed ...

Experts are sounding the alarm about increased use of kratom and about highly concentrated products containing 7-OH, a more ...

Vanda Pharma announces Bysanti NDA with US filing; US FDA decision expected in early 2026: Washington Tuesday, May 6, 2025, 18:00 Hrs [IST] Vanda Pharmaceuticals Inc. (Vanda) anno ...

Net Loss: BioXcel Therapeutics had a net loss of $7.3 million for the first quarter of 2025, compared to a net loss of $26.8 ...

Discover the Best Kratom Strains and Products for Natural Energy, Focus, and Motivation - Featuring Super Speciosa's Clean, ...

In England, 5.5 million people have high blood pressure without knowing - bad sleep, medications, contraception and stress ...

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.